BG105302A - Means for improving cognition - Google Patents

Means for improving cognition

Info

Publication number
BG105302A
BG105302A BG105302A BG10530201A BG105302A BG 105302 A BG105302 A BG 105302A BG 105302 A BG105302 A BG 105302A BG 10530201 A BG10530201 A BG 10530201A BG 105302 A BG105302 A BG 105302A
Authority
BG
Bulgaria
Prior art keywords
improving cognition
acetylcholinesterase
alzheimer
inhibitor
administered
Prior art date
Application number
BG105302A
Other languages
Bulgarian (bg)
English (en)
Inventor
NIJS Paul Leonce DE
Wim Louis PARYS
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG105302A publication Critical patent/BG105302A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BG105302A 1998-10-16 2001-03-01 Means for improving cognition BG105302A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Publications (1)

Publication Number Publication Date
BG105302A true BG105302A (en) 2001-11-30

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105302A BG105302A (en) 1998-10-16 2001-03-01 Means for improving cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (xx)
JP (1) JP2002527469A (xx)
KR (1) KR20010072878A (xx)
CN (1) CN1367697A (xx)
AU (1) AU6472799A (xx)
BG (1) BG105302A (xx)
BR (1) BR9914419A (xx)
CA (1) CA2345767A1 (xx)
EE (1) EE200100136A (xx)
HK (1) HK1039745A1 (xx)
HR (1) HRP20010262A2 (xx)
HU (1) HUP0103781A3 (xx)
ID (1) ID28441A (xx)
IL (1) IL142588A0 (xx)
NO (1) NO20011403L (xx)
PL (1) PL348107A1 (xx)
SK (1) SK4592001A3 (xx)
TR (1) TR200101082T2 (xx)
WO (1) WO2000023057A2 (xx)
ZA (1) ZA200103081B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
JP5067998B2 (ja) * 2001-10-30 2012-11-07 ノバルティス アーゲー イロペリドンおよび星形ポリマーのデポー製剤
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
WO2004084905A2 (en) * 2003-03-24 2004-10-07 University Of Florida Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2006065233A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
CA2108880A1 (en) * 1991-05-14 1992-11-15 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
WO1999007378A1 (en) * 1997-08-11 1999-02-18 THE UNIVERSITY OF SOUTH FLORIDA A Corporation of the State of Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Also Published As

Publication number Publication date
AU6472799A (en) 2000-05-08
WO2000023057A2 (en) 2000-04-27
IL142588A0 (en) 2002-03-10
CA2345767A1 (en) 2000-04-27
NO20011403D0 (no) 2001-03-20
WO2000023057A3 (en) 2000-07-27
TR200101082T2 (tr) 2001-09-21
ZA200103081B (en) 2002-07-12
CN1367697A (zh) 2002-09-04
NO20011403L (no) 2001-03-20
HRP20010262A2 (en) 2002-06-30
KR20010072878A (ko) 2001-07-31
PL348107A1 (en) 2002-05-06
BR9914419A (pt) 2001-06-26
HK1039745A1 (zh) 2002-05-10
SK4592001A3 (en) 2001-12-03
EE200100136A (et) 2002-06-17
HUP0103781A3 (en) 2003-09-29
ID28441A (id) 2001-05-24
HUP0103781A2 (hu) 2002-03-28
JP2002527469A (ja) 2002-08-27
EP1121131A2 (en) 2001-08-08

Similar Documents

Publication Publication Date Title
BG105302A (en) Means for improving cognition
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
BR0008059A (pt) Composições de valdecoxib
HK1029043A1 (en) Remedy for neurodegenerative diseases.
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
AU2002307049A1 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
ATE240115T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose
BG105256A (en) Muscarinic agonists and antagonists
IL149134A0 (en) Pharmaceutical compositions containing tofisopam
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
AU4568400A (en) Sphingomyelinase inhibitor
RS60604A (xx) Derivati karboksamidina i njihova upotreba u tretiranju vaskularnih oboljenja
GEP20043377B (en) Pharmaceutical Complex
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders